Drug Profile
CGP 47072
Latest Information Update: 07 Sep 1998
Price :
$50
*
At a glance
- Originator Novartis
- Class Bisphosphonates; Calcium regulators; Osteoporosis therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 07 Sep 1998 No-Development-Reported for Postmenopausal osteoporosis (Unknown route)
- 18 Apr 1995 New profile
- 18 Apr 1995 Preclinical development for Postmenopausal osteoporosis (Unknown route)